A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05780034
- Locations
- ๐บ๐ธ
University of Texas Southwestern Medical Center, Dallas, Texas, United States
๐บ๐ธSwedish Cancer Institute, Seattle, Washington, United States
๐บ๐ธColorado Blood Cancer Institute, Denver, Colorado, United States
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 8
- Registration Number
- NCT05673109
- Locations
- ๐จ๐ณ
Site 2004, Hunan, China
๐จ๐ณSite 2003, Guangzhou, China
๐จ๐ณSite 2001, Beijing, China
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05654532
- Locations
- ๐บ๐ธ
Site 02, Sarasota, Florida, United States
๐บ๐ธSite 03, Houston, Texas, United States
๐บ๐ธSite 01, Nashville, Tennessee, United States
A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 6
- Registration Number
- NCT05489679
- Locations
- ๐จ๐ณ
Site 1003, Hangzhou, China
๐จ๐ณSite 1001, Beijing, China
๐จ๐ณSite 1002, Tianjin, China
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 28
- Registration Number
- NCT05241613
- Locations
- ๐บ๐ธ
Site 03, Sarasota, Florida, United States
๐บ๐ธSite 01, Nashville, Tennessee, United States
๐บ๐ธSite 04, Dallas, Texas, United States
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 21
- Registration Number
- NCT05080842
- Locations
- ๐บ๐ธ
Site 03, Nashville, Tennessee, United States
๐บ๐ธSite 02, Sarasota, Florida, United States
๐บ๐ธSite 01, Denver, Colorado, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath